These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27708247)

  • 1. Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.
    Pradhan S; Mahajan D; Kaur P; Pandey N; Sharma C; Srivastava T
    Oncotarget; 2016 Nov; 7(44):71841-71855. PubMed ID: 27708247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
    Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
    Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
    Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
    Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
    Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
    PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
    Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
    Lee EJ; Lee BB; Kim SJ; Park YD; Park J; Kim DH
    Int J Oncol; 2008 Oct; 33(4):767-76. PubMed ID: 18813790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
    Takai N; Ueda T; Nishida M; Nasu K; Narahara H
    Int J Mol Med; 2006 Feb; 17(2):323-9. PubMed ID: 16391833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions.
    Lee JG; Shin JH; Shim HS; Lee CY; Kim DJ; Kim YS; Chung KY
    Respir Res; 2015 Nov; 16():138. PubMed ID: 26553068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
    Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
    Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
    Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29945926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer.
    Wang M; Li G; Yang Z; Wang L; Zhang L; Wang T; Zhang Y; Zhang S; Han Y; Jia L
    Oncotarget; 2017 Jan; 8(5):8083-8094. PubMed ID: 28042952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
    Shin DH; Choi YJ; Park JW
    Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
    Lai SL; Perng RP; Hwang J
    J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.